The U.S. District Court has granted the FTC’s motion to block Edwards Lifesciences’ acquisition of JenaValve Technology, leading Edwards to cancel the deal. Despite disagreement with the decision, Edwards has revised its 2026 adjusted earnings per share guidance to $2.90-$3.05, up from the previous range of $2.80-$2.95. Analysts anticipate earnings of $2.87 per share for the fiscal year, excluding special items.

Read more at Nasdaq: U.S. Court Blocks Edwards Lifesciences’ Acquisition Of JenaValve; Company Revises 2026 Adj. EPS View